Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6613660 | 0.85 | KMT2A (0.59) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL7437362 | 0.84 | LMNA (0.55) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL16108072 | 0.83 | MEN1 (0.50) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL4823776 | 0.83 | MAPT (0.49) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL3470803 | 0.81 | MEN1 (0.52) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL7851443 | 0.81 | MAPT (0.50) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL10884646 | 0.80 | MAPT (0.51) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL7439413 | 0.79 | MAPT (0.45) | TSHRMAPTLMNAGAAMEN1 | |
| SCHEMBL3780281 | 0.78 | MAPT (0.66) | MAPTLMNAKMT2ACDC25BTDP1 | |
| SCHEMBL28764382 | 0.78 | MAPT (0.44) | TSHRMAPTLMNAGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1191249-C | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2005-03-02 | — | — | CN | disclosed |
| CN-1403453-A | Quinoline and quinazoline compound for treating benign prostatic hyperplasia specially | PFIZER (US) | 2003-03-19 | — | — | CN | disclosed |
| CN-1093858-C | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2002-11-06 | — | — | CN | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| CN-1243513-A | Quinoline and quinazoline compounds for the treatment, in particular for the treatment of benign prostatic hyperplasia | PFIZER LTD (US) | 2000-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | TSHR 2000/4885MAPT 2899/4885LMNA 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.